V
Victoria Szenes
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 14
Citations - 270
Victoria Szenes is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Rituximab & T cell. The author has an hindex of 4, co-authored 13 publications receiving 140 citations.
Papers
More filters
Journal ArticleDOI
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J Curran,Kevin J Curran,Steven P. Margossian,Steven P. Margossian,Nancy A. Kernan,Nancy A. Kernan,Lewis B. Silverman,Lewis B. Silverman,David A. Williams,David A. Williams,Neerav Shukla,Rachel Kobos,Christopher J. Forlenza,Peter G. Steinherz,Peter G. Steinherz,Susan E. Prockop,Susan E. Prockop,Farid Boulad,Farid Boulad,Barbara Spitzer,Barbara Spitzer,Maria Cancio,Maria Cancio,Jaap Jan Boelens,Andrew L. Kung,Yasmin Khakoo,Yasmin Khakoo,Victoria Szenes,Jae H. Park,Craig S. Sauter,Glenn Heller,Xiuyan Wang,Brigitte Senechal,Richard J. O'Reilly,Isabelle Riviere,Michel Sadelain,Renier J. Brentjens +36 more
TL;DR: The data supports the safety of CD19-specific CAR T cell therapy for R/R B-ALL and suggest that dose intensity of conditioning chemotherapy and minimal pre-treatment disease burden have a positive impact on response without a negative effect on toxicity.
Journal ArticleDOI
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
Craig S. Sauter,Craig S. Sauter,Brigitte Senechal,Isabelle Riviere,Ai Ni,Yvette Bernal,Xiuyan Wang,Terence J. Purdon,Malloury Hall,Ashvin N. Singh,Victoria Szenes,Sarah Yoo,Ahmet Dogan,Yongzeng Wang,Craig H. Moskowitz,Sergio Giralt,Matthew J. Matasar,Miguel-Angel Perales,Kevin J. Curran,Jae H. Park,Jae H. Park,Michel Sadelain,Renier J. Brentjens,Renier J. Brentjens +23 more
TL;DR: 19-28z CAR T cells following HDT-ASCT was associated with a high-incidence of reversible neurotoxicity and CRS, and effector CD4+ and CD8+ immunophenotypes may improve disease control.
Journal ArticleDOI
Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL
Kevin J. Curran,Isabelle Riviere,Lewis B. Silverman,Lewis B. Silverman,Rachel Kobos,Neerav Shukla,Peter G. Steinherz,Farid Boulad,Susan E. Prockop,Andromachi Scaradavou,Steven P. Margossian,Steven P. Margossian,Xiuyan Wang,Yongzeng Wang,Victoria Szenes,Colleen Dansereau,Brenda Mackinnon,Craig S. Sauter,Jae H. Park,Nancy A. Kernan,Richard J. O'Reilly,Michel Sadelain,Renier J. Brentjens +22 more
TL;DR: Early results demonstrate the feasibility and significant clinical impact of this approach in patients with relapsed B-ALL and demonstrate the tolerability of this technology in patients in a multicenter trial to include a collaborating institution.
Journal ArticleDOI
Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant
Susan E. Prockop,Ekaterina Doubrovina,Irene Rodriguez-Sanchez,Aisha Hasan,Juliet N. Barker,Hugo Castro-Malaspina,Parastoo B. Dahi,Sergio Giralt,Boglarka Gyurkocza,Nancy A. Kernan,Guenther Koehne,Esperanza B. Papadopoulos,Doris M. Ponce,Craig S. Sauter,Virginia Escobedo,Victoria Szenes,Karim Baroudy,Alison Slocum,Richard J. O'Reilly +18 more
TL;DR: Adoptive immunotherapy with transplant donor-derived virus-specific T-cells is effective in the treatment of CMV viremia and disease complicating allogeneic hematopoietic stem cell transplant, but is not available if the donor is seronegative or unavailable to provide lymphocytes.
Proceedings ArticleDOI
Abstract CT107: Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder
Susan E. Prockop,Ekaterina Doubrovina,Karim Baroudy,Farid Boulad,Ramzi Khalaf,Esperanza B. Papadopoulos,Craig S. Sauter,Victoria Szenes,Stephanie Suser,Gloria Wasilewski,Julianna Ruggierio,Richard J. O'Reilly +11 more
TL;DR: EBV-CTLs produce high response rates that are durable; pts who achieved CR had no relapses of EBV LPD; the OS in both studies far exceeded the survival reported for this patient population.